Heres what to know about this in-demand drug
Semaglutide is a GLP-1 receptor agonist , originally developed for managing type 2 diabetes
Route of Administration Insights Why Did the Subcutaneous Injection Segment Dominate the Market in 2025
Although changes in the appearance of the feet and other areas of the body are common with major weight loss, I rarely see this as a primary concern for patients
One randomized controlled trial that included 78 participants with metabolic syndrome and NAFLD found 90 days of treatment with a supplement providing 250 mg silymarin plus 60 IU vitamin E daily, along with a diet and exercise program, reduced waist circumference, BMI, liver size, and scores on non-invasive measures of NAFLD compared with diet and exercise alone
Generic carnitine can sometimes contain impurities